Zydus Lifesciences has signed an exclusive development, licensing, supply and commercialisation agreement with Synthon BV of the Netherlands for a novel 505(B)(2) Oncology product for an undisclosed target.

Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product. Zydus will be responsible for the NDA submission and commercialization of the product in the US.

This 505(B)(2) Oncology product will likely be filed in 2026 and will be offering additional strengths that is intended to provide reduced pill burden, flexibility for dose adjustment and enhanced patient compliance.

Speaking on the development, Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., said, “We are pleased to partner with Synthon for the commercialisation of this complex drug product in the US market. The partnership will bring access to a high unmet need therapy area. We are certain that by pooling our resources and knowledge, we will meet critical needs of patients and stakeholders.”

Anish Mehta, CEO of Synthon BV, stated, “This 505(B)(2) product is another example of Synthon’s superior complex product development capability and represents a strategic move toward more complex and clinically differentiated products. We are excited to strengthen our partnership with Zydus, who will bring this critical medicine to market to provide patients with important treatment alternatives for this extremely challenging condition.”